Testing a new drug for advanced solid tumors
Part of Cancer clinical trials.
This trial tests a new drug called ALK202 for people with advanced solid tumors that have not responded to other treatments. The study aims to see if the drug is safe and to find the best dose.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 to 75 years old.
- You have a solid tumor that has spread or cannot be removed with surgery.
- You have at least one tumor that can be measured on a scan.
- Your doctor expects you to live at least 3 more months.
- You are in good enough health to do daily activities without help.
- You have not had an organ or bone marrow transplant.
- You have not had a live vaccine in the last 4 weeks.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug, ALK201, in people with advanced solid tumors that have not responded to other treatments. It aims to see if the drug is safe and can shrink tumors.
This trial tests a new injectable drug called ALK-N001 in people with advanced solid tumors that have stopped responding to standard treatment. It's for various cancers including lung, breast, ovarian, cervical, pancreatic, liver, and esophageal cancer. The goal is to see if the drug can shrink tumors or slow their growth.
This study tests a new combination cancer medicine (ALK202) for non-small cell lung cancer that hasn't responded to standard treatments. The goal is to see if this drug combination shrinks tumors and is safe to take.
This Phase 1 trial tests APG-2449, a new drug, in people with advanced solid tumors—especially certain lung cancers that have ALK or ROS1 gene fusions. Because it’s an early safety-and-dose study, it may help learn how well the drug works and what doses are safe.
This study tests a new drug called ALK201 combined with another drug (ivonescimab) to see if they are safe and help people with a type of lung cancer called squamous non-small cell lung cancer. If you join, you may receive the combination treatment and be closely monitored.
This Phase 2 study tests whether ALK-targeted drugs can shrink or control advanced squamous cell cancer that has spread. You may be eligible if your tumor has an ALK gene rearrangement and you have not had prior cancer medicines for this stage.
Hear when a new Advanced Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.